New research supports pridopidine's neuroprotective properties in Huntington's Disease models

Newly published papers further elucidate the mechanisms underlying pridopidine's neuroprotective properties through activation of the Sigma-1 Receptor (S1R). Pridopidine enhances mitochondrial function and reduces mHTT-induced ER stress, which are impaired in HD, mediated by the S1R. Three new peer-reviewed publications highlight pridopidine's therapeutic potential and provide data supporting the role of the S1R in neurodegenerative diseases

Prilenia Therapeutics B.V., a clinical stage biotech company focused on developing novel treatments for neurodegenerative and neurodevelopmental disorders, today announces the publication of three peer-reviewed journal articles, highlighting key aspects of the mechanism of action of its lead asset, END